Oral @entity2177 for treatment of XXXX following @entity5806 wounds of the foot.

@entity1 @entity4713 @entity796 @entity5806 @entity2688 @entity2177 @entity794 @entity281 @entity325
From January 1990 to December 1993, 23 adults were hospitalized at our institution for treatment of @entity281 that occurred following @entity5806 wounds. All 23 @entity1 had @entity2688 , and 14 had signs of @entity4713 on a roentgenogram or a 99mTc bone scan. After undergoing surgical intervention that consisted of debridement, drainage of the pus, and exploration of the bones, @entity1 received intravenous @entity2177 (400 mg b.i.d.) for 24 hours, followed by an oral regimen (750 mg b.i.d.). Nine @entity1 with @entity2688 received oral therapy for 7 days, and the 14 @entity1 with @entity4713 received oral therapy for 14 days. Isolates that were recovered included @entity796 (18 @entity1 ) and @entity794 (2 @entity1 ); one @entity1 had a @entity325 , and in two cases no pathogens were recovered. All of the isolates were susceptible to @entity2177 . All @entity1 were cured, and none had reinfection. Our results show that @entity281 following a @entity5806 wound may be treated with oral @entity2177 (750 mg b.i.d.) for 7-14 days, provided that surgery is performed first.
